2022
Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies
DOLEŽALOVÁ, Lenka, Lucie BLÁHOVÁ, Jan KUTA, Tereza HOJDAROVÁ, Šárka KOZÁKOVÁ et. al.Základní údaje
Originální název
Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies
Autoři
DOLEŽALOVÁ, Lenka (203 Česká republika, domácí), Lucie BLÁHOVÁ (203 Česká republika, domácí), Jan KUTA (203 Česká republika, domácí), Tereza HOJDAROVÁ (203 Česká republika, domácí), Šárka KOZÁKOVÁ (203 Česká republika) a Luděk BLÁHA (203 Česká republika, garant, domácí)
Vydání
Environmental Science and Pollution Research, Heidelberg, Springer Heidelberg, 2022, 0944-1344
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.800
Kód RIV
RIV/00216224:14310/22:00125197
Organizační jednotka
Přírodovědecká fakulta
UT WoS
000725470500032
Klíčová slova anglicky
Surface contamination; Occupational exposure; Antineoplastic drugs; Hospital pharmacy; 5-fluorouracil; Cyclophosphamide; Platinum derivatives; Gemcitabine
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 4. 2023 09:49, Mgr. Marie Šípková, DiS.
Anotace
V originále
The consumption of hazardous antineoplastic drugs (ADs) used in anticancer chemotherapies is steadily increasing representing thus risks to both human health and the environment. Hospitals may serve as a contamination source, and pharmacists preparing the antineoplastic drugs (ADs) as well as nurses administering chemotherapy and caring for oncology patients are among the healthcare professionals being highly exposed. Here, we present the results of systematic monitoring (2018-2020) of surface contamination by 13 ADs in the pharmacies and hospitals in the Czech Republic (CZ; large-scale monitoring, 20 workplaces) and Slovak Republic (SK; pilot study at 4 workplaces). The study evaluated contamination by three commonly monitored ADs, i.e., 5-fluorouracil (FU), cyclophosphamide (CP), and platinum (total Pt representing cis-, carbo-, and oxaliplatin) together with ten less explored ADs, i.e., gemcitabine (GEM), ifosfamide (IF), paclitaxel (PX), irinotecan (IRI), docetaxel (DOC), methotrexate (MET), etoposide (ETOP), capecitabine (CAP), imatinib (IMAT), and doxorubicin (DOX). Floors and desktop surfaces in hospitals (chemotherapy application rooms, nurse working areas) were found to be more contaminated, namely with CP and Pt, in both countries when compared to pharmacies. Comparison between the countries showed that hospital surfaces in SK are generally more contaminated (e.g., CP median was 20 times higher in SK), while some pharmacy areas in the CZ were more contamined in comparison with SK. The newly studied ADs were detected at lower concentrations in comparison to FU, CP, and Pt, but some markers (GEM, IF, PX, and IRI) were frequently observed, and adding these compounds to routine monitoring is recommended.
Návaznosti
EF17_043/0009632, projekt VaV |
| ||
LM2018121, projekt VaV |
| ||
NV18-09-00188, projekt VaV |
|